UFC FIGHT PASS ® to Be Made Available on VIDAA-Powered Hisense and Toshiba Smart TVs
UFC®, the world’s premier mixed martial arts organization, and Hisense, the world-class technology company, today announced a distribution and marketing collaboration centered on UFC FIGHT PASS®, the world’s leading subscription streaming service for combat sports, which will be released on VIDAA-powered Hisense and Toshiba smart TVs.
Starting in August, UFC FIGHT PASS will be distributed on new select Hisense TVs as well as on Toshiba Smart TVs manufactured by Hisense that utilize the VIDAA smart platform, a Linux-based open smart TV operating system that is present on products in more than 120 countries around the world.
UFC FIGHT PASS provides subscribers with access to live UFC events; live local mixed martial arts and combat sports from around the world; original series and historical programming; and the world’s largest fight library, featuring more than 20,000 bouts from dozens of combats sports organizations, as well as every fight in UFC history.
As an official marketing partner of UFC, Hisense branding will be featured in the world-famous Octagon® at select UFC events for the remainder of 2021. In addition, Hisense will be the presenting partner of select UFC digital content distributed across UFC social media platforms in the United Kingdom, Ireland, Europe, and the Middle East.
“We are delighted to partner with Hisense and VIDAA to deliver the incredible combat sports content on UFC FIGHT PASS to more fans than ever before,” said Crowley Sullivan, Vice President and General Manager of UFC FIGHT PASS. “This collaboration is a win-win, as it will help us expand our global reach for FIGHT PASS, while exposing Hisense products to UFC’s fan base in key markets.”
“Partnering with UFC, the world leader in MMA, is a big step in bringing the best sports content to our VIDAA users. I believe that we can grow our businesses faster together, since VIDAA is present in almost every country in the world and UFC is becoming increasingly more popular outside the U.S. as well,” said Guy Edri, Executive Vice President for Business Development for VIDAA.
UFC® is the world’s premier mixed martial arts organization (MMA), with more than 625 million fans and 155 million social media followers. The organization produces more than 40 live events annually in some of the most prestigious arenas around the world, while broadcasting to approximately 900M TV households across more than 175 countries. UFC’s athlete roster features the world’s best MMA athletes representing more than 70 countries. The organization’s digital offerings include UFC FIGHT PASS®, one of the world’s leading streaming services for combat sports. UFC is owned by global entertainment, sports and content company Endeavor, and is headquartered in Las Vegas, Nevada. For more information, visit UFC.com and follow UFC at Facebook.com/UFC, Twitter, Snapchat, Instagram and TikTok: @UFC.
Hisense currently has more than 90,000 employees worldwide, together with 16 industrial parks and 16 research and development centres, which comprise a multinational collaborative research and development system. Its business includes multimedia, home appliances, IT intelligent information systems and the modern service industry, while its products have been exported to over 160 countries and regions. According to an independent research and consultancy firm, Hisense remains the world’s fourth-largest TV maker in terms of unit shipments (per 2020 figures).
VIDAA is a Linux-based open smart TV operating system. Established in 2014, it has - in just six years - become a strong global contender in the smart TV platform space. In 2020, VIDAA introduced a completely new and revamped user interface named 4.0, which puts users and their way of consuming content at the core of the design. The latest version of VIDAA - U5 was launched in May 2021. VIDAA is preinstalled on new Hisense TVs as well as Toshiba Smart TVs manufactured by Hisense. For more information, visit www.vidaa.com and follow VIDAA on Facebook.com/vidaatv, Twitter, and Instagram at @vidaatv.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Press Contact for UFC:
+44 7800 513 876
Press Contact for VIDAA:
+386 31 689 862
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors May Contribute to the Significant Under-Diagnosis of Migraine21.6.2021 14:01:00 CEST | Press release
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today presented new epidemiology data on migraine from the State of Israel which indicate that socio-economic factors may contribute to underdiagnosis of migraine across society1. A retrospective study of migraine epidemiology in Southern Israel, supported by Teva and presented at the virtual 7th Congress of the European Academy of Neurology (EAN), found extreme variability in the prevalence of diagnosed patients with migraine across the geographic area studied. Prevalence rates were positively associated with the socio-economic status of the geographic area studied, suggesting that those living with migraine from less advantaged areas may find it harder to achieve an accurate diagnosis and thereby access appropriate therapy. “These findings are concerning not least because they suggest significant ‘migraine awareness inequity’ in this population,” said Professor Gal Ifergane, study investigator, practitioner, head of the Depart
New Data Supporting the Safety and Efficacy Profile of AJOVY® (fremanezumab) Shared at 7th European Academy of Neurology Congress21.6.2021 14:01:00 CEST | Press release
A new analysis presented by Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) on AJOVY® (fremanezumab) injection for the preventive treatment of migraine, indicates to the European neurology community that the medicine has a positive safety profile in relation to risk of cardiovascular events. The data, drawn from an analysis of three published Phase 3 studies of fremanezumab and presented at the 7th Congress of the European Academy of Neurology (EAN), showed minimal changes in the heart rate and blood pressure of those patients studied over a 12 week period. 1 “As a CGRP inhibitor, fremanezumab has been shown to provide protection against migraine in suitable patients, and we remain focused on continued assessment of the safety profile of this therapy, particularly in relation to heart-related issues as it is believed CGRP itself acts as a ‘safeguard’ during cardiovascular ischemia and other events,” said Dr Joshua M. Cohen, Senior Director and Global Therapeutic Area Lead, Mi
Ambarella Expands Security AI Vision SoC Portfolio With Two New Families; Doubles Resolution to 32MP30 for 4K Multi-Imager Cameras With Advanced AI21.6.2021 11:00:00 CEST | Press release
Ambarella, Inc. (NASDAQ: AMBA), an AI vision silicon company, today announced the expansion of its AI vision SoC portfolio with the new CV5S and CV52S security families. Based on the CVflow® architecture and advanced 5nm process technology, the new SoCs support simultaneous 4K encoding and advanced AI processing in a single low-power design, which provides industry-leading edge AI SoC performance per watt. The CV5S family is ideal for security camera applications that require multiple sensors for 360-degree coverage, over a wide area and with a long range, such as outdoor city environments or large buildings. The CV52S family is designed for single-sensor security cameras with advanced AI performance that need to more clearly identify individuals or objects in a scene, including faces and license plate numbers over long distances, such as ITS traffic cameras. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005178/en/ Am
Ezbob Introduces New SaaS Platform to Meet the Changing Landscape of Digital Banking21.6.2021 11:00:00 CEST | Press release
Ezbob Ltd., an innovator in customer acquisition technology for financial services, today announced the introduction of a new modular SaaS platform that addresses key trends in the sector. The company’s Ezbob Express™, focuses on three important needs: offering financial service providers the flexibility of filling gaps in their digital transformation strategies, enabling them to make more precise complex credit and risk decisions in real-time, and facilitating the growth of embedded finance. Ezbob’s new Express customer acquisition platform has a modular approach, enabling financial institutions with gaps in their digital channel to add the functionality needed to achieve a customised digital experience. The new modules include: UX & Process Design, Compliance & Authentication, Credit & Risk Decisioning and Product Recommender. Since its inception Ezbob has been providing digital onboarding services for many well-known financial institutions including Santander, NatWest, Metro Bank, P
Jardiance ® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction21.6.2021 10:36:00 CEST | Press release
The European Commission has granted marketing authorization for Jardiance® (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer Ingelheim and Eli Lilly and Company have announced.The extension of the indication follows a positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) on 20 May 2021.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005298/en/ “Today’s approval provides an important new treatment option which can now help the millions of people in Europe living with symptomatic chronic heart failure with reduced ejection fraction,” said Faiez Zannad, M.D., Ph.D., EMPEROR Program clinical investigator and Emeritus Professor of Therapeutics at the University of Lorraine, France. “New treatment options such as empagliflozin can save lives and help people spend less time in the hospital and mor
SK Capital Reaches Agreement to Sell Niacet for $1,015m21.6.2021 10:00:00 CEST | Press release
An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today that it reached agreement to sell Niacet Corp. (“Niacet”) to Kerry Group plc, the global taste and nutrition company, for $1,015m (€853m¹) on a cash-free, debt-free basis, subject to customary closing adjustments. Following the acquisition, Niacet will be integrated into Kerry’s global food protection and preservation platform. Jack Norris, Managing Director at SK Capital, said, “SK Capital is privileged to have partnered with Kelly Brannen and the entire Niacet team. We are proud and appreciative of Niacet’s accomplishments over the last four years leveraging the strong foundation the Brannen family built over many decades. We believe Niacet is well-positioned to continue this growth and flourish under Kerry’s ownership. We wish Kerry and all the employees of Niacet every success.” Kelly Brannen, CEO and significant minority owner of Niacet, commented, “We are proud of the rich heritage we have bui
ISAE-SUPAERO's "Collaborative Rover and Drone" Project, Facilitating the Exploration of the Moon21.6.2021 09:54:00 CEST | Press release
While Thomas Pesquet launched on April 22 as part of the Alpha mission, one of humanity's biggest challenges remains even further away than the ISS, 400,000 km from Earth: the establishment of a lunar base. But before being able to settle on the Moon in a prolonged way to exploit its resources or as a logistic support for future exploration missions further away, an exploration work is necessary. The use of autonomous robotic systems would allow mapping of dangerous or hard-to-reach areas from space, before eventually deploying infrastructure such as a spaceport or human habitation. Faced with this exploration challenge, the Space Advanced Concepts Laboratory (SaCLaB) of ISAE-SUPAERO in Toulouse and a team of students from the Institute are developing the Collaborative Rover and Drone (CoRoDro) project to study navigation and autonomous operations for space robotic systems. This scientific study is one of 12 university technology projects selected in 8 different countries as part of th